Irbesartan Teva

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
05-09-2023

Ingredient activ:

irbesartan

Disponibil de la:

Teva B.V.

Codul ATC:

C09CA04

INN (nume internaţional):

irbesartan

Grupul Terapeutică:

Agents acting on the renin-angiotensin system

Zonă Terapeutică:

Hypertension

Indicații terapeutice:

Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.

Rezumat produs:

Revision: 16

Statutul autorizaţiei:

Authorised

Data de autorizare:

2009-10-30

Prospect

                                35
B. PACKAGE LEAFLET
36 PACKAGE LEAFLET: INFORMATION FOR THE USER
IRBESARTAN TEVA 75 MG FILM-COATED TABLETS
Irbesartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Irbesartan Teva is and what it is used for
2.
What you need to know before you take Irbesartan Teva
3.
How to take Irbesartan Teva
4.
Possible side effects
5.
How to store Irbesartan Teva
6.
Contents of the pack and other information
1.
WHAT IRBESARTAN TEVA IS AND WHAT IT IS USED FOR
Irbesartan Teva belongs to a group of medicines known as
angiotensin-II receptor antagonists.
Angiotensin-II is a substance produced in the body which binds to
receptors in blood vessels causing
them to tighten. This results in an increase in blood pressure.
Irbesartan Teva prevents the binding of
angiotensin-II to these receptors, causing the blood vessels to relax
and the blood pressure to lower.
Irbesartan Teva slows the decrease of kidney function in patients with
high blood pressure and type 2
diabetes.
Irbesartan Teva is used in adult patients

to treat high blood pressure
_(essential hypertension)_

to protect the kidney in patients with high blood pressure, type 2
diabetes and laboratory
evidence of impaired kidney function.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE IRBESARTAN TEVA
DO NOT TAKE IRBESARTAN TEVA

If you are
ALLERGIC
to irbesartan or to any of the other ingredients of this medicine
(listed in
section 6).

If you are
MORE THAN 3 MONTHS PREGNANT
(it is also better to avoid Irbesartan Teva in early
pregnancy - see pregnanc
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Irbesartan Teva 75 mg film-coated tablets
Irbesartan Teva 150 mg film-coated tablets
Irbesartan Teva 300 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Irbesartan Teva 75 mg film-coated tablets
Each film-coated tablet contains 75 mg of irbesartan
Irbesartan Teva 150 mg film-coated tablets
Each film-coated tablet contains 150 mg of irbesartan
Irbesartan Teva 300 mg film-coated tablets
Each film-coated tablet contains 300 mg of irbesartan
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Irbesartan Teva 75 mg film-coated tablets
White to off white capsule shaped, film coated tablet. One side of the
tablet debossed with the number
“93”. The other side of the tablet debossed with number
“7464”.
Irbesartan Teva 150 mg film-coated tablets
White to off white capsule shaped, film coated tablet. One side of the
tablet debossed with the number
“93”. The other side of the tablet debossed with number
“7465”.
Irbesartan Teva 300 mg film-coated tablets
White to off white capsule shaped, film coated tablet. One side of the
tablet debossed with the number
“93”. The other side of the tablet debossed with number
“7466”.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Irbesartan Teva is indicated in adults for the treatment of essential
hypertension.
It is also indicated for the treatment of renal disease in adult
patients with hypertension and type 2
diabetes mellitus as part of an antihypertensive medicinal product
regimen (see sections 4.3, 4.4, 4.5
and 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The usual recommended initial and maintenance dose is 150 mg once
daily, with or without food.
Irbesartan at a dose of 150 mg once daily generally provides a better
24 hour blood pressure control
than 75 mg. However, initiation of therapy with 75 mg could be
considered, particularly in
haemodialysed patients and in the elderly over 75 years.
3
In patie
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului bulgară 05-09-2023
Raport public de evaluare Raport public de evaluare bulgară 16-11-2009
Prospect Prospect spaniolă 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului spaniolă 05-09-2023
Raport public de evaluare Raport public de evaluare spaniolă 16-11-2009
Prospect Prospect cehă 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului cehă 05-09-2023
Raport public de evaluare Raport public de evaluare cehă 16-11-2009
Prospect Prospect daneză 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului daneză 05-09-2023
Raport public de evaluare Raport public de evaluare daneză 16-11-2009
Prospect Prospect germană 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului germană 05-09-2023
Raport public de evaluare Raport public de evaluare germană 16-11-2009
Prospect Prospect estoniană 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului estoniană 05-09-2023
Raport public de evaluare Raport public de evaluare estoniană 16-11-2009
Prospect Prospect greacă 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului greacă 05-09-2023
Raport public de evaluare Raport public de evaluare greacă 16-11-2009
Prospect Prospect franceză 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului franceză 05-09-2023
Raport public de evaluare Raport public de evaluare franceză 16-11-2009
Prospect Prospect italiană 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului italiană 05-09-2023
Raport public de evaluare Raport public de evaluare italiană 16-11-2009
Prospect Prospect letonă 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului letonă 05-09-2023
Raport public de evaluare Raport public de evaluare letonă 16-11-2009
Prospect Prospect lituaniană 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului lituaniană 05-09-2023
Raport public de evaluare Raport public de evaluare lituaniană 16-11-2009
Prospect Prospect maghiară 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului maghiară 05-09-2023
Raport public de evaluare Raport public de evaluare maghiară 16-11-2009
Prospect Prospect malteză 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului malteză 05-09-2023
Raport public de evaluare Raport public de evaluare malteză 16-11-2009
Prospect Prospect olandeză 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului olandeză 05-09-2023
Raport public de evaluare Raport public de evaluare olandeză 16-11-2009
Prospect Prospect poloneză 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului poloneză 05-09-2023
Raport public de evaluare Raport public de evaluare poloneză 16-11-2009
Prospect Prospect portugheză 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului portugheză 05-09-2023
Raport public de evaluare Raport public de evaluare portugheză 16-11-2009
Prospect Prospect română 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului română 05-09-2023
Raport public de evaluare Raport public de evaluare română 16-11-2009
Prospect Prospect slovacă 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului slovacă 05-09-2023
Raport public de evaluare Raport public de evaluare slovacă 16-11-2009
Prospect Prospect slovenă 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului slovenă 05-09-2023
Raport public de evaluare Raport public de evaluare slovenă 16-11-2009
Prospect Prospect finlandeză 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului finlandeză 05-09-2023
Raport public de evaluare Raport public de evaluare finlandeză 16-11-2009
Prospect Prospect suedeză 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului suedeză 05-09-2023
Raport public de evaluare Raport public de evaluare suedeză 16-11-2009
Prospect Prospect norvegiană 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului norvegiană 05-09-2023
Prospect Prospect islandeză 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului islandeză 05-09-2023
Prospect Prospect croată 05-09-2023
Caracteristicilor produsului Caracteristicilor produsului croată 05-09-2023

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor